



CASE REPORT

Bell's palsy during interferon alpha 2a treatment in a case with Behçet uveitis [v1; ref status: indexed, <http://f1000r.es/27j>]

Fatime Nilüfer Yalçındağ, Cem Alay

Department of Ophthalmology, Ankara University Faculty of Medicine, Ankara, Turkey

v1 **First Published:** 15 Nov 2013, 2:245 (doi: 10.12688/f1000research.2-245.v1)
Latest Published: 15 Nov 2013, 2:245 (doi: 10.12688/f1000research.2-245.v1)

Abstract

Purpose: To present a case who developed Bell's palsy while using interferon alpha 2a for Behçet uveitis.

Methods: A patient with Behçet disease presented with decreased vision in his right eye. Ophthalmic examination, fundus fluorescein angiography and optical coherence tomography were performed. After developing facial paralysis while on interferon therapy, the patient was referred to our neurology service for differential diagnosis and treatment.

Results: Examination of right eye revealed panuveitis with branch retinal vein occlusion, so high dose steroids were prescribed. In three days there was no improvement in terms of vitreous inflammation and so steroids were replaced with interferon. At the seventh month, patient experienced a facial paralysis. After eliminating other causes, including viral infections, trauma, cold exposure and neurological evaluation with cranial MRI, the patient was diagnosed to have Bell's palsy by a neurologist. Interferon was replaced with mycophenolate mofetil and the Bell's palsy was treated with oral steroids.

Conclusion: It is important to be alert to both common and rare complications while treating with interferon.

Article Status Summary

Referee Responses

Referees	1	2
v1 published 15 Nov 2013	 report	 report

1 **Erkan Alpsoy**, Akdeniz University Turkey

2 **Sumru Onal**, Marmara University School of Medicine Turkey

Latest Comments

No Comments Yet

Corresponding author: Cem Alay (drcemalay@yahoo.com)

How to cite this article: Yalçındağ FN, Alay C (2013) Bell's palsy during interferon alpha 2a treatment in a case with Behçet uveitis [v1; ref status: indexed, <http://f1000r.es/27j>] *F1000Research* 2013, 2:245 (doi: 10.12688/f1000research.2-245.v1)

Copyright: © 2013 Yalçındağ FN et al. This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

Grant information: The author(s) declared that no grants were involved in supporting this work.

Competing Interests: No competing interests were disclosed.

First Published: 15 Nov 2013, 2:245 (doi: 10.12688/f1000research.2-245.v1)

First Indexed: 10 Feb 2014, 2:245 (doi: 10.12688/f1000research.2-245.v1)

Introduction

Interferon alpha 2a is a recombinant biological agent that is used for the treatment of several diseases including chronic hepatitis C, hairy cell leukemia, Philadelphia chromosome positive chronic myelogenous leukemia (CML) and AIDS-related Kaposi's sarcoma. It is also used in Behçet uveitis that is refractory to conventional immunosuppressive agents^{1,2}. The central (CNS) and peripheral nervous system (PNS) can be affected while using interferon alpha 2a. There are two existing case reports describing Bell's palsy associated with interferon treatment for chronic hepatitis C infection^{3,4}. Here we present another case report indicating Bell's palsy during interferon alpha 2a treatment in Behçet uveitis.

Case report

A 27-year old Turkish, male, taxi driver who has Behçet's Disease was referred to our clinic for a decrease in visual acuity in his right eye for 2 days. At presentation, the best-corrected visual acuity was 20/320 in his right eye and 20/20 in his left eye. On slit lamp examination, there were keratic precipitates, anterior chamber cells and vitreous cells in his right eye. Fundus examination revealed optic disc edema, macular edema and abundant intraretinal hemorrhages in the inferior temporal part of retina. His left eye seemed to be normal. Optical coherence tomography (Cirrus HD-OCT Model 4000, Carl Zeiss Meditec) (OCT) and fluorescein angiography (FA) was then performed. Central macular thickness (CMT) was 595 µm on OCT. In FA, there was mild hyperfluorescence on both optic discs. In addition, hypofluorescence in the inferior retinal areas due to hemorrhages and staining on the vessel walls in right eye was spotted. Macular edema and peripheral ischemia were also evident. A diagnosis of panuveitis with inferior temporal branch retinal vein occlusion due to Behçet's Disease was made.

Firstly, high dose steroids (1 gram/day methylprednisolone, intravenously) were prescribed to the patient for 3 days. Dexamethasone eye drops every hour during the day and topical cyclopentolate 1% three times a day were also prescribed. On the third day, the anterior chamber reaction seemed to be decreased but no improvement was observed, either in the vitreous inflammation or the macular edema. As such, the initial high dose steroid treatment was stopped and interferon alpha 2a (Roferon-A, Roche Pharmaceuticals, Hoffmann-La Roche Inc., Switzerland) 4.5 million IU (MIU) subcutaneously on alternate days and 10 mg/day oral prednisolone were prescribed to the patient. At that point, we had decided upon interferon treatment because the patient was young and the first ocular presentation of Behçet's disease was seriously threatening in terms of visual prognosis. In addition, green argon laser photocoagulation was applied to the ischemic areas of the retina.

The patient was examined weekly for the first month in order to observe the effects of treatment closely. After this, the follow-up was done monthly. In the first month, steroid treatment was tapered slowly and stopped while interferon treatment was continued. In the first 6 months, no adverse effects were observed, best corrected visual acuity improved to 20/32 and the panuveitis and macular edema regressed. CMT was 230 µm after the 6-months of interferon alpha 2a therapy. There were no signs of anterior uveitis or vitreous inflammation. The patient's oral aphthae, genital ulcers and arthralgia (symptoms of Behçet's Disease) were also improved. At this stage,

the dose of interferon alpha 2a was tapered to 3 MU on alternate days.

One month after tapering the dose, the patient experienced difficulty in closing his right eyelid and stiffness in the right half of his face. His wife also reported that there had been no movement on the right side of his face for about 15 days. There was no history of trauma, infection, cold exposure or any other predisposing factors that might have explained this situation. The patient was tested for several viral infections including herpes viruses, cytomegalovirus (CMV) and Epstein-Barr virus (EBV). All tests were negative. Afterwards, in order to eliminate neurological problems such as brain tumor, stroke or neuro-Behçet disease, the patient was immediately referred to our neurology service. Cranial MRI was normal and the neurological evaluation revealed no pathological findings apart from facial paralysis. As such the patient was diagnosed with Bell's palsy. Interferon use was considered as a possible reason for this condition and so interferon treatment was tapered and discontinued. Mycophenolate mofetil (720 mg/day, oral) was prescribed for Behçet's disease because the patient had previously experienced nausea and vomiting with azathioprine, which had been prescribed before as an initial therapy for Behçet's disease by a rheumatologist. Oral methylprednisolone 48 mg per day was prescribed by the neurologist and gradually tapered (8 mg per week) over 6 weeks. In addition, a program of exercises for the facial muscles was recommended. All symptoms of Bell's palsy disappeared within 2 months of onset.

Discussion

There is a wide variety of adverse effects due to the use of interferon alpha 2a, including flu-like syndrome (unusual tiredness, fever, chills, muscle aches, and joint pain), injection site reaction (redness, pain at the site of injection), proneness to serious infections, new or worsening autoimmune disease⁵⁻⁷, myelosuppression^{8,9}, depression, suicide, suicidal thoughts, and cardiovascular problems^{10,11} such as hypotension or hypertension, arrhythmia and myocardial infarction. Patients may also suffer from nausea, vomiting, loss of appetite, diarrhea, cough, dry mouth, dizziness, vertigo, sweating, itching, hair loss, fatigue, abdominal pain, constipation, sore throat, insomnia¹², anxiety and numbness.

Interferon alpha 2a also affects the CNS and PNS. Difficulty of concentration and aggression are the most common CNS problems. Decrease in mental activity, dysphasia, dysarthria, aphasia, aphonia, amnesia, multiple sclerosis-like disease¹³, transient ischemic attacks, encephalopathy, confusion, somnolence and coma may also occur during the use of interferon. It is also known that several symptoms such as ataxia, paresthesia, tremor and peripheral neuropathies¹⁴⁻¹⁸ can be seen if the PNS is affected. In our patient, we encountered Bell's palsy, a peripheral neuropathy affecting the facial nerve in the 7th month of interferon therapy. No elucidating factors but interferon were present at the time we diagnosed the patient. Hitherto, there have been two other reports of Bell's palsy related to the use of interferon^{3,4}. So it was important for us to call attention to our case as an example of a rare complication of interferon use. In conclusion, physicians should always keep an eye on patients who are being treated with interferon alpha 2a. Physicians should be alert to the rare side effects of interferon treatment as well as the more common and well-known side effects of this agent.

Consent

Written informed consent for publication of his clinical details was obtained from the patient.

Author contributions

Dr. Alay participated in drafting the article and Dr. Yalçındağ revised it critically for intellectual content. Dr. Alay and Dr. Yalçındağ were involved in the assessment and treatment of the patient. Both

authors gave final approval of the version to be submitted and revised version.

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Kötter I, Zierhut M, Eckstein AK, *et al.*: **Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.** *Br J Ophthalmol.* 2003; **87**(4): 423–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Yalçındağ FN, Uzun A: **Results of Interferon Alpha-2a Therapy in Patients with Behçet's Disease.** *J Ocul Pharmacol Ther.* 2012; **28**(4): 439–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Ogundipe O, Smith M: **Bell's palsy during interferon therapy for chronic hepatitis C infection in patients with haemorrhagic disorders.** *Haemophilia.* 2000; **6**(2): 110–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hoare M, Woodall T, Alexander GJ: **Bell's palsy associated with IFN-alpha and ribavirin therapy for hepatitis C virus infection.** *J Interferon Cytokine Res.* 2005; **25**(3): 174–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Rizvi R, Hojati M: **Interferon- α induced lupus in a patient with chronic hepatitis C virus.** *J Clin Rheumatol.* 2011; **17**(3): 152–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Savvas SP, Papakostas N, Giannaris M, *et al.*: **Interferon alpha-induced hashimoto thyroiditis followed by transient graves disease in a patient with chronic HCV infection.** *South Med J.* 2010; **103**(6): 585–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Yang D, Arkfeld D, Fong TL: **Development of anti-CCP-positive rheumatoid arthritis following pegylated interferon- α 2a treatment for chronic hepatitis C infection.** *J Rheumatol.* 2010; **37**(8): 1777.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Zizer E, Bommer M, Barth T, *et al.*: **Severe agranulocytosis as a rare side effect of pegylated interferon therapy for chronic hepatitis B.** *Z Gastroenterol.* 2011; **49**(5): 596–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hajder J, Stanislavljević N, Marković O, *et al.*: **Late onset of severe thrombocytopenia during interferon treatment for chronic hepatitis C infection--case report.** *Srp Arh Celok Lek.* 2010; **138**(3–4): 240–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Roche NC, Paule P, Kerebel S, *et al.*: **Complete atrio-ventricular block: a rare complication of interferon alpha therapy.** *Presse Med.* 2011; **40**(3): 316–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Velasco J, Oriñuela I, Sanjuán AZ, *et al.*: **Pericardial effusion associated to interferon in an immunocompetent patient.** *Enferm Infecc Microbiol Clin.* 2010; **28**(10): 749–50.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Raison CL, Rye DB, Woolwine BJ, *et al.*: **Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol.** *Biol Psychiatry.* 2010; **68**(10): 942–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Matsuo T, Takabatake R: **Multiple sclerosis-like disease secondary to alpha interferon.** *Ocul Immunol Inflamm.* 2002; **10**(4): 299–304.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Knyazer B, Lifshitz T, Marcus M, *et al.*: **Anterior ischemic optic neuropathy in a patient with hepatitis C treated with interferon-alpha and ribavirin.** *Isr Med Assoc J.* 2011; **13**(4): 251–3.
[PubMed Abstract](#)
- Khiani V, Kelly T, Shibli A, *et al.*: **Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection.** *World J Gastroenterol.* 2008; **14**(2): 318–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Tunca A, Erbayrak M, Aytac S, *et al.*: **Axonal neuropathy and hearing loss associated with alpha interferon treatment in chronic hepatitis B: a case report.** *Turk J Gastroenterol.* 2004; **15**(2): 97–9.
[PubMed Abstract](#)
- Fukumoto Y, Shigemitsu T, Kajii N, *et al.*: **Abducent nerve paralysis during interferon alpha-2a therapy in a case of chronic active hepatitis C.** *Intern Med.* 1994; **33**(10): 637–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bauherz G, Soeur M, Lustman F: **Oculomotor nerve paralysis induced by alpha II-interferon.** *Acta Neurol Belg.* 1990; **90**(2): 111–4.
[PubMed Abstract](#)

Current Referee Status:

Referee Responses for Version 1



Sumru Onal

Uveitis Service, Department of Ophthalmology, Marmara University School of Medicine, Uskudar, Istanbul, Turkey

Approved: 10 February 2014

Referee Report: 10 February 2014

This manuscript by Yalcindag and Alay reports on a patient with Bell's palsy that occurred as a possible adverse effect of interferon alfa-2a that was prescribed in an effort to control Behçet uveitis. It is a well-written paper and will contribute to practicing ophthalmologists. My comments are listed below:

1. I would suggest that the authors name the disease as "Behçet disease" rather than "Behçet's disease" throughout the paper. The intraocular inflammation has already been well addressed as "Behçet uveitis".
2. There is need for revision of the English grammar and language.
3. I would recommend that the authors include information from the World Health Organization's causality assessment of suspected adverse drug reactions in the discussion section. The authors should also classify their observations based on this classification. It seems to me that the described finding is a possible adverse effect. The reference would be: "Edwards IR, Biriell C. [Harmonisation in pharmacovigilance](#). *Drug Saf* 1994;10:93–102." The classification is as follows:

Certain: A clinical event, including laboratory test abnormality, occurring in a plausible time relationship to drug administration that cannot be explained by concurrent disease or other drugs or chemicals. The response to withdrawal of the drug (dechallenge) should be clinically plausible. The event must be definitive pharmacologically or phenomenologically, using satisfactory rechallenge procedure if necessary.

Probable/likely: A clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug, unlikely to be attributed to concurrent disease or other drugs or chemicals, which follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge information is not required to fulfil this definition.

Possible: A clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug, which could also be explained by concurrent disease, or other drugs or chemicals, or underlying disease provide plausible explanations.

Unlikely: A clinical event, including laboratory test abnormality, with a temporal relationship to drug administration that makes a causal relationship improbable and in which other drugs, chemicals, or underlying disease provide plausible explanations.

Conditional/unclassified: A clinical event, including laboratory test abnormality, reported as an adverse reaction, about which more data are essential for a proper assessment or the additional

data are undergoing examination.

Nonassessable/unclassified: A report suggesting an adverse reaction that cannot be judged because information is insufficient or contradictory and that cannot be supplemented or verified.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.



Erkan Alpsoy

Department of Dermatology and Venerology, Faculty of Medicine, Akdeniz University, Antalya, Turkey

Approved: 14 January 2014

Referee Report: 14 January 2014

This is a well-organised and well-written paper and I am sure that it will be helpful to readers in this field. I only have one minor comment: that the English Language should be checked and grammatical mistakes corrected.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.
